Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

the similarity between FYB206 and Keytruda® was confirmed across multiple parameters such as structure, purity, and potency. This comprehensive data package lays a strong foundation for the ...

In just the past two years, the S&P 500 has amassed some incredible gains, rising by around 60% during that stretch. It's an incredible performance when you consider its long-run average is a return ...

Keytruda has been a top-selling drug for years ... Carvana will need to run a tight ship to ensure it is able to stay out of the red. Last year, it incurred an operating loss of $72 million.

Merck's Q2 beat was driven by strong Keytruda sales and growth in oncology ... expected sales of the Gardasil vaccine, impacted by shipment delays in China. Merck's lowered adjusted profit ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... of a superior data package, including stability data ...

Your vote at this year’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for December 17, 2024, is ...